Links and background information about U.S. public policy affecting prescription drugs and prescription drug coverage.

Provides information to the public on the prescription drug reimportation war being fought between the pharmaceutical industry and America.

Provides facts, tips and news about importing prescription drugs from Canada.

Allows consumers to gauge savings on nearly 50 of the most popular prescription medications by picking multiple drugs, different dosage settings and time horizons ranging from one month to 20 years.

Sources for the debate over prescription drug coverage in Medicare.

An article about a federal judge that struck down a Food and Drug Administration regulation that required drug makers to test medicines routinely given to children. Arianna Huffington, Alternet.

DrugsNotDogFood.com is a petition to President Bush to support coverage for prescription drugs for seniors. For each signature, we send a dog biscuit to the President to show the extreme plight of many seniors -- forced to choose between medicine and food.

Calling for reform of the FDA.

A non-profit organization that represents the interests of consumers in drug policy and believes that all drugs marketed should be acceptably safe, effective, affordable and meet real medical needs.

Discusses pharmaceutical industry marketing, promotion, and sales practices and how they may adversely affect prescription drug prescribing practices, and increase prescription drug prices.

An article from Red Flags Weekly that suggests pharmaceutical and chemical companies profit from the sale of herbicides, pesticides, and household chemicals as well as the prescription drugs often needed to treat health problems caused by these household and industrial chemicals.

National coalition of consumer groups fighting against illegal drug industry price manipulation deceptive marketing.

Article describing the push for easier, cheaper cross-border Canadian-American prescriptions.

An article from Alternet that examines the effects of the patent system in the pharmaceutical industry and suggests that increased public funding of pharmaceutical research and development could dramatically lower costs for consumers.